ArticleContemporary clinical trials2012
Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Article in Contemporary clinical trials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials.Cancer · 2025Review
- Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels.Entropy (Basel, Switzerland) · 2024Article
- A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies.Statistical methods in medical research · 2024Article
- A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials.Trials · 2023Article
- Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?Brazilian journal of biometrics · 2022Article
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.Biometrical journal. Biometrische Zeitschrift · 2021Article
- On the properties of the toxicity index and its statistical efficiency.Statistics in medicine · 2021Article
- A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.Stats · 2020Article
- Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs.Contemporary clinical trials communications · 2018Article
- A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.Journal of biopharmaceutical statistics · 2018Article
- How to keep high-risk studies ethical: classifying candidate solutions.Journal of medical ethics · 2017Article
- Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.Journal of biometrics & biostatistics · 2017Article
- Article
- Approaches for informing optimal dose of behavioral interventions.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2014Review
- Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.Statistics in medicine · 2014Article
- Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.Contemporary clinical trials · 2014Article
- Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.The open medical informatics journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Escalation with overdose control (EWOC) is a Bayesian adaptive design for selecting dose levels in cancer Phase I clinical trials while controlling the posterior probability of exceeding the maximum tolerated dose (MTD). EWOC has been used by clinicians to design many cancer Phase I clinical trials, see e.g. [1-4]. However, this design treats the toxicity response as a binary indicator of dose limiting toxicity (DLT) and does not account for the number and specific grades of toxicities experienced by patients during the trial. Chen et al. (2010) proposed a novel toxicity score system to fully utilize all toxicity information using a normalized equivalent toxicity score (NETS). In this paper, we propose to incorporate NETS into EWOC using a quasi-Bernoulli likelihood approach to design cancer Phase I clinical trials. We call the design escalation with overdose control using normalized equivalent toxicity score (EWOC-NETS). Simulation results show that this design has good operating characteristics and improves the accuracy of MTD, trial efficiency, therapeutic effect, and overdose control relative to EWOC which is used as a representative of designs treating toxicity response as a binary indicator of DLT. We illustrate the performance of this design using real trial data in identifying the Phase II dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.